London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies
Engitix, a British BioTech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a €21 million ($25 million) Series A extension financing.
The financing was provided by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital Management.
“Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics,” said Giuseppe Mazza, CEO and co-founder of Engitix. “Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated, ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes.”
In the European BioTech and drug-development sector, 2025 saw continued capital deployment across oncology, fibrosis and adjacent therapeutic areas, placing Engitix’s €21 million Series A extension within a broader pattern of mid- to late-stage funding activity.
Comparable rounds include TargED Biopharmaceuticals in the Netherlands, which secured €21.5 million to advance targeted thrombotic disease therapies, closely mirroring Engitix in both stage and funding size. Larger oncology-focused raises were reported for FoRx Therapeutics in Switzerland (€42 million for DNA-repair cancer therapies), Adcytherix in France (€105 million for novel antibody-drug conjugates), and Tubulis in Germany (€308 million to expand its ADC pipeline).
The UK has also remained active, with Trogenix raising €80 million to accelerate cancer treatments and Scripta Therapeutics securing over €10 million for its drug-discovery platform, making Engitix part of a cluster of British BioTech financings this year.
Additional activity includes Italy-based NanoPhoria (€83.5 million for a heart-failure therapy) and Ireland’s Aerska (€17 million for RNAi medicines targeting brain diseases).
Taken together, these rounds account for well over €600 million in disclosed BioTech funding in 2025, indicating sustained investor interest in therapeutics platforms.
Founded in 2016, Engitix is a BioTech company developing therapies that target the extracellular matrix (ECM) to treat cancer and fibrosis. By integrating large-scale ECM datasets with translational biology and drug development, Engitix aims to build a pipeline of differentiated therapeutics designed to act within disease tissue microenvironments.
The company has a strategic drug discovery partnership with Dompé farmaceutici and development collaborations with Takeda in advanced fibrotic liver diseases.
Mike Platt, Investor Director, added: “Engitix has developed a compelling strategy at the intersection of data, biology, and drug development. I’m pleased to continue supporting Engitix as it advances its programmes in fibrosis and solid tumours.”
The new proceeds will be used to continue preclinical development across Engitix’s proprietary ECM-targeted pipeline in solid tumours and fibrosis, and to further expand and apply Engitix’s platform built on one of the largest proprietary ECM datasets in these diseases.
The post London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies appeared first on EU-Startups.
